Skip to main content

DaVita Value Stock - Dividend - Research Selection

Davita

ISIN: US23918K1088 , WKN: 897914

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Buffett’s $24 Billion Selling Spree: The 6 Stocks Berkshire Hathaway Dumped

2025-12-23
Investors began to notice that Warren Buffett began being more conservative with the stock market three years ago, and that streak has continued even as the S&P 500 hit new peaks and beyond. He sold Apple (NASDAQ:AAPL), Bank of America (NYSE:BAC), VeriSign (NASDAQ:VRSN), DaVita (NYSE:DVA), D.R. Horton (NYSE:DHI), and Nucor (NYSE:NUE) as of Q3 2025. ... Buffett’s $24 Billion Selling Spree: The 6 Stocks Berkshire Hathaway Dumped

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

2025-12-22
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.

Zacks Industry Outlook Highlights Encompass Health, DaVita, Option Care Health and The Pennant

2025-12-22
Encompass Health is in focus as outpatient and home healthcare shifts toward AI, telehealth and cost-efficient care models.

Balancing a Kidney Diet: Optimizing Nutrition Through Personalization

2025-12-22
NORTHAMPTON, MA / ACCESS Newswire / December 22, 2025 / DaVita: For individuals managing chronic kidney disease (CKD), dietary choices significantly impact health outcomes and disease progression. A kidney-friendly diet often involves managing intake ...

DaVita (DVA): Reassessing Valuation After a 23% Year-to-Date Share Price Decline

2025-12-20
DaVita (DVA) has quietly slipped this year, with the stock down about 23% year to date and roughly 24% over the past year, despite steady revenue and earnings growth. See our latest analysis for DaVita. The recent slide in DaVita’s share price, including a weaker 7 day share price return and a double digit year to date share price decline, contrasts with its solid three year total shareholder return. This suggests momentum has cooled even as the long term story remains intact. If DaVita’s...

2,000+ Volunteer Hours: DaVita Teammates Connect With Communities During Week of Service

2025-12-19
NORTHAMPTON, MA / ACCESS Newswire / December 19, 2025 / DaVita: A DaVita teammate helps organize medically tailored meals as part of a service event for Project Angel Food. From November 13-19, DaVita teammates (employees) brought the kidney care ...

4 Outpatient Home Health Stocks in Focus as Market Dynamics Change

2025-12-19
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.

Here's Why You Should Hold DaVita Stock in Your Portfolio for Now

2025-12-18
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

Is DaVita Stock Underperforming the Dow?

2025-12-15
As DaVita has underperformed relative to the Dow over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Do DaVita’s New Strategy and People Chiefs Subtly Recast Its Long‑Term Story (DVA)?

2025-12-12
DaVita Inc. recently expanded its executive leadership team by appointing long-time leaders Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective December 11, 2025. By elevating internal talent to oversee people operations and corporate strategy, DaVita is signaling a stronger focus on culture and long-term kidney care innovation. We’ll now examine how Hendrickson’s people leadership and Phillips’s expanded strategy remit may influence DaVita’s...